Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Cripto Polyclonal Antibody, Biotin

Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA522698
Description
In Western blot a band is seen at ~18 kDa representing the core form of Cripto1, and at ~36 kDa reporesenting the glycosylated/ post-translationally modified form. Suggested positive control: MDA-MB231 (human breast cancer) lysates.
Cripto (TDGF1) is a GPI-anchored cell membrane proetin involved in Nodal signaling. Cell associated TDGF1 acts as a a Nodeal coreceptor in cis. Shedding of TDGF1 by TMEM8A modulated Nodal signaling by allowing soluble TDGF1 to act as a Nodal coreceptor on other cells. TDGF1 is expressed both in ES cells and during the early phases of embryo development, while in adults it is reactivated in a wide range of epithelial cancers.
Specifications
| Cripto | |
| Polyclonal | |
| Biotin | |
| TDGF1 | |
| CR; CR1; CRGF; CRIPTO; cripto growth factor; Cripto-1; cripto-1 growth factor; Cripto-3; epidermal growth factor-like Cripto protein; epidermal growth factor-like cripto protein CR1; Tdgf1; TDGF2; teratocarcinoma-derived growth factor; teratocarcinoma-derived growth factor 1; TERATOCARCINOMA-DERIVED GROWTH FACTOR PRECURSOR (EPIDERMAL GROWTH FACTOR-LIKE CRIPTO PROTEIN) (CRIPTO GROWTH FACTOR) | |
| Rabbit | |
| Antigen affinity chromatography | |
| RUO | |
| 21667, 6997 | |
| 4°C, store in dark | |
| Liquid |
| Flow Cytometry, Western Blot, Immunocytochemistry | |
| 0.85 mg/mL | |
| PBS with 0.05% sodium azide | |
| P13385, P51865 | |
| TDGF1 | |
| A synthetic peptide made to an N-terminal portion of mouse Cripto1 (between residues 1-50). | |
| 100 μL | |
| Primary | |
| Human, Mouse | |
| Antibody | |
| IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction